Coronavirus increases sales of high-tech mobile X-ray machines

Micro-X’s DRX Revolution Nano is in hot demand. Image credit:

Media Release

South Australian high-tech X-ray manufacturer Micro-X’s sales to Asia and Europe continue to increase due to the coronavirus.

The Adelaide-based company this morning reported to the Australian Securities Exchange that sales of its flagship lightweight mobile X-ray machine reached $1.8 million in the quarter, with $1 million worth of sales over the past 20 days. Did.

With about four weeks left in the March quarter, this result is already well below December quarter’s DRX Revolution Nano sales of $384,000 and almost the same as the $1.9 million in sales achieved in the entire 2019 fiscal year. They are equivalent.

The latest batch of orders must be delivered urgently within 4 weeks. These additional purchase orders are for shipping to Asia and Europe.

The company said that while the order through distributor Carestream Health did not specify an end customer, due to the size and urgency of the order, some of these nano units will be sold during the ongoing COVID-19 pandemic. It is understood that the aircraft will be deployed in connection with. outbreak.

Nano’s standard delivery time is 8 to 12 weeks from order date, but Micro-X says a recent February order was delivered within about four weeks from order date.

Initial diagnosis of coronavirus is made by blood tests to confirm the infectious agent, and chest X-rays are used as an important part of diagnosing the onset and progression of severity of the disease. As with pneumonia, chest x-rays are used to detect fluid in the lungs, especially in patients who present with severe acute respiratory distress.

Micro-X Managing Director Peter Rowland said the mobile X-ray imaging unit offers a flexible use that best suits the requirements of infection control procedures and the nature of the hospital’s temporary isolation building.

“We are pleased that our nanomobile X-ray devices are being used to aid in the diagnosis and management of this novel respiratory virus at a time when this infectious disease outbreak is alarming.” Stated.

“For most patients, COVID-19 infection begins and ends in the lungs. Like influenza, coronavirus is a respiratory disease, and chest X-rays still show pneumonia-like symptoms caused by severe coronavirus infection. Because it’s an important tool to monitor progress.”

“The number of countries currently ordering Nano shows growing awareness of the product and its capabilities, which will lead to increased adoption and long-term benefits.”

The surge in demand for mobile X-ray machines comes at a critical time for Micro-X, following disappointing sales in the December quarter.

Additional X-ray imaging capabilities are being introduced in many countries to meet the needs of the growing number of coronavirus cases.

Micro-X’s stock price rose to 36 cents in September, but fell steadily following weak results, and was worth just 13 cents in early February. After the company first announced its coronavirus sales on February 13, the stock price reached 20 cents on February 17 and was at 19 cents at noon today.

Micro-X relocated from Victoria to South Australia in 2015, establishing a manufacturing hub at the Tonsley Innovation District, a former Mitsubishi Motors assembly plant in Adelaide’s southern suburbs.

We also listed on the ASX in December 2015 and launched DRX Revolution Nano in 2017. The unit is manufactured using carbon nanotubes, making the Nano several times lighter and more compact than traditional he x-ray machines.

Micro-X also develops rover mobile X-ray machines for military hospitals, mobile backscatter imagers for remote detection of improvised explosive devices, and mobile baggage scanners for airports.

A version of this story first appeared in The Leads South Australia. Source:
Image credit:

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button